Oxford Immunotec Global (NASDAQ:OXFD) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

Several other equities research analysts also recently commented on OXFD. ValuEngine downgraded Oxford Immunotec Global from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 1st. Piper Jaffray Companies reissued an “overweight” rating on shares of Oxford Immunotec Global in a report on Sunday, November 11th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Oxford Immunotec Global presently has an average rating of “Buy” and a consensus price target of $16.67.

Shares of NASDAQ OXFD traded up $0.02 during trading hours on Thursday, hitting $14.90. The company had a trading volume of 106,517 shares, compared to its average volume of 104,300. The company has a market cap of $387.25 million, a PE ratio of -10.96 and a beta of 0.11. Oxford Immunotec Global has a 1-year low of $10.00 and a 1-year high of $19.19.

Oxford Immunotec Global (NASDAQ:OXFD) last released its quarterly earnings data on Friday, November 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.14). The company had revenue of $16.10 million during the quarter, compared to analyst estimates of $33.60 million. Oxford Immunotec Global had a negative net margin of 12.51% and a negative return on equity of 41.15%. The company’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.70) EPS. As a group, equities analysts predict that Oxford Immunotec Global will post -1.09 EPS for the current fiscal year.

In other Oxford Immunotec Global news, CEO Peter Wrighton-Smith sold 10,000 shares of the firm’s stock in a transaction on Thursday, January 10th. The stock was sold at an average price of $14.91, for a total transaction of $149,100.00. Following the completion of the sale, the chief executive officer now owns 423,469 shares of the company’s stock, valued at approximately $6,313,922.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $15.50, for a total value of $46,500.00. Following the sale, the director now directly owns 9,000 shares of the company’s stock, valued at approximately $139,500. The disclosure for this sale can be found here. Company insiders own 6.61% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc lifted its holdings in Oxford Immunotec Global by 2.0% during the 3rd quarter. Vanguard Group Inc now owns 95,647 shares of the company’s stock valued at $1,552,000 after purchasing an additional 1,839 shares during the last quarter. Marshall Wace LLP bought a new position in Oxford Immunotec Global during the 3rd quarter worth $1,305,000. Penn Capital Management Co. Inc. increased its position in Oxford Immunotec Global by 5.5% during the 3rd quarter. Penn Capital Management Co. Inc. now owns 271,280 shares of the company’s stock worth $4,403,000 after buying an additional 14,254 shares during the period. TIAA CREF Investment Management LLC increased its position in Oxford Immunotec Global by 16.4% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 122,591 shares of the company’s stock worth $1,990,000 after buying an additional 17,244 shares during the period. Finally, Neuberger Berman Group LLC bought a new position in Oxford Immunotec Global during the 3rd quarter worth $1,298,000. 90.94% of the stock is owned by institutional investors and hedge funds.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Recommended Story: Earnings Reports

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.